| Identification | Back Directory | [Name]
BGC 20-1531 (hydrochloride) | [CAS]
1962928-26-2 | [Synonyms]
AP 1531
BGC20-1531
(PGN-1531
AP-1531 hydrochloride
GTPL3380 hydrochloride
BGC 20-1531 (hydrochloride)
BGC201531 hydrochloride(1186532615 free base),BGC 20 1531 hydrochloride(1186532 61 5 free base)
4-[[4-(5-Methoxy-2-pyridinyl)phenoxy]methyl]-5-methyl-N-[(2-methylphenyl)sulfonyl]-2-furancarboxamide hydrochloride | [Molecular Formula]
C26H25ClN2O6S | [MDL Number]
MFCD30182277 | [MOL File]
1962928-26-2.mol | [Molecular Weight]
529 |
| Hazard Information | Back Directory | [Description]
BGC 20-1531 is a potent and selective antagonist of the prostaglandin E2 (PGE2; ) receptor subtype 4 (EP4) with Ki values of 11.7, >10,000, and >10,000 nM for EP4, EP2, and EP3, respectively. It is selective for EP4, exhibiting <50% inhibition at 47 ion channels, cell-surface transporters, enzymes, and nuclear receptors at a concentration of 10 μM. BGC 20-1531 antagonizes PGE2-induced cAMP accumulation in a dose-dependent manner in HEK293 EBNA cells that stably express human EP4 receptors. It also reverses PGE2-induced vasorelaxation (Kb = 15.85 nM) in human middle cerebral and middle meningeal arterial rings. BGC 20-1531 prevents PGE2-induced increases in carotid blood flow and decreases in carotid resistance with an ID50 value of 5 mg/kg in dogs. | [Uses]
BGC 20-1531 Hydrochloride, is a potent and selective EP4 antagonist, exhibiting <50% inhibition at 47 ion channels, cell-surface transporters, enzymes, and nuclear receptors at a concentration of 10 μM. It also Inhibits PGE2-induced vasodilation of middle cerebral and meningeal arterieshuman middle cerebral and middle meningeal arterial rings. | [storage]
Desiccate at RT |
|
|